scholarly journals Real-life effectiveness of fluticasone furoate/vilanterol after switching from fluticasone/salmeterol or budesonide/formoterol therapy in patients with symptomatic asthma: Relvar Ellipta for Real Asthma Control Study (RERACS study)

2020 ◽  
Vol 12 (5) ◽  
pp. 1877-1883
Author(s):  
Yasuo Shimizu ◽  
Taichi Shiobara ◽  
Ryo Arai ◽  
Kazuyuki Chibana ◽  
Akihiro Takemasa
Keyword(s):  
Asthma Control ◽  
Real Life ◽  
Fluticasone Furoate ◽  
Life Effectiveness ◽  
Symptomatic Asthma ◽  
Control Study

Budesonide/formoterol maintenance and reliever therapy in asthma control: Acute, dose-related effects and real-life effectiveness

Respirology ◽  
2014 ◽  
Vol 20 (2) ◽  
pp. 264-272 ◽  
Author(s):  
Ching-Hsiung Lin ◽  
Jeng-Yuan Hsu ◽  
Yi-Han Hsiao ◽  
Ching-Min Tseng ◽  
Vincent Yi-Fong Su ◽  
...  
Keyword(s):  
Asthma Control ◽  
Real Life ◽  
Life Effectiveness ◽  
Acute Dose

scholarly journals “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study

2009 ◽  
Vol 103 (11) ◽  
pp. 1633-1642 ◽  
Author(s):  
G. Brusselle ◽  
A. Michils ◽  
R. Louis ◽  
L. Dupont ◽  
B. Van de Maele ◽  
...  
Keyword(s):  
Allergic Asthma ◽  
Real Life ◽  
Life Effectiveness

Predicting the Effectiveness of the Pfizer-BioNTech BNT162b2 Vaccine from SARS-CoV-2 Variants Neutralisation Data

2021 ◽  
Author(s):  
Oleg Volkov ◽  
Svetlana Borozdenkova ◽  
Alexander Gray
Keyword(s):  
Real Life ◽  
Vaccine Effectiveness ◽  
Vaccine Protection ◽  
Life Effectiveness ◽  
Correlates Of Protection ◽  
Antibody Titres ◽  
Effectiveness Studies

Modelling frameworks for vaccine protection are sorely needed to fight the Covid-19 pandemic with vaccines. We propose such a framework for the BNT162b2 and potentially other vaccines. It identifies correlates of protection based on live SARS-CoV-2 variants neutralising antibody titres from vaccinated individuals. We applied it to predict vaccine effectiveness in overall populations and age subgroups. It was validated by predicting effectiveness against the B.1.167.2 (Delta) variant. The predictions, of 51.7% (34%, 69%) after one and of 88.6% (76%, 97%) after two vaccine doses, were close to the corresponding means, 49% and 85.4%, of observations in real-life effectiveness studies. We illustrate its applications to inform decisions, such as about the doses and timing of vaccine boosters.

Sign in / Sign up

Export Citation Format

Share Document